<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="n95/PMC7079862/results/search/funders/results.xml">
  <result pre="0001 2157 2938 Institute of Health Policy Management and Evaluation," exact="University of Toronto," post="[5], grid.416745.5 Department of Critical Care Medicine, Sunnybrook Hospital,"/>
  <result pre="Department of Medicine, Division of Infectious Diseases and International Health," exact="University of Virginia" post="School of Medicine, epub: 2020-2-2 ppub: 2020 46 2"/>
  <result pre="Division of Infectious Diseases and International Health, University of Virginia" exact="School of Medicine," post="epub: 2020-2-2 ppub: 2020 46 2 315 328 received:"/>
  <result pre="source. These permissions are granted for the duration of the" exact="World Health Organization" post="(WHO) declaration of COVID-19 as a global pandemic. Abstract"/>
  <result pre="supplement for references Infection control precautions are based on the" exact="Centers for Disease Control and Prevention" post="at: https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/type-duration-precautions.html#M, https://www.cdc.gov/coronavirus/mers/infection-prevention-control.html, https://www.cdc.gov/infectioncontrol/guidelines/isolation/appendix/standard-precautions.html, https://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm (all accessed on Dec"/>
  <result pre="earliest [ 9]. Nevertheless, the Clinical Practice Guidelines by the" exact="Infectious Diseases Society of America" post="(IDSA) recommends oseltamivir for all hospitalized patients with influenza,"/>
  <result pre="only intravenous influenza antiviral agent currently approved by the US" exact="Food and Drug Administration" post="(FDA). Intravenous zanamivir has been recently approved by the"/>
  <result pre="infection control precautions for different RVIs as recommended by the" exact="Centers for Disease Control and Prevention" post="(please refer to Table 2 footnote for CDC references)."/>
  <result pre="The Global Influenza Programme has published the updated WHO Public" exact="Health Research" post="Agenda for Influenza, in which research priorities were identified"/>
  <result pre="a non-paid consultant on antiviral active for MERS-coronavirus (CoV) for" exact="Gilead Sciences" post="and SAB Biotherapeutics. Dr. Hayden’s institution received funding from"/>
  <result pre="Sciences and SAB Biotherapeutics. Dr. Hayden’s institution received funding from" exact="GlaxoSmithKline" post="(Data Safety Monitoring Board [DSMB] member for influenza randomized-controlled"/>
  <result pre="Vaccitech (DSMB chair for influenza RCTs); he received honoraria from" exact="World Health Organization" post="(consultant on influenza and emerging viral infections) and the"/>
  <result pre="been a non-paid consultant on antivirals active for MERS-CoV for" exact="Gilead Sciences," post="SAB Biotherapeutics, and Regeneron, and for multiple companies on"/>
  <result pre="the Ford Haitian Orphanage and School for his consulting time;" exact="Shionogi" post="and Roche have provided meeting travel support. References References"/>
  <result pre="Haitian Orphanage and School for his consulting time; Shionogi and" exact="Roche" post="have provided meeting travel support. References References 1. Karhu"/>
  <result pre="the treatment of respiratory syncytial virus (RSV) in hospitalized adults" exact="American Thoracic Society" post="2018 international conference, San Diego, 2018: abstract A4457 5."/>
 </snippets>
</snippetsTree>
